Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.3% – Should You Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shot up 5.3% during mid-day trading on Friday . The company traded as high as $7.68 and last traded at $7.59. 5,773,886 shares were traded during trading, a decline of 46% from the average session volume of 10,779,051 shares. The stock had previously closed at $7.21.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Stock Performance

The stock has a market capitalization of $3.05 billion, a PE ratio of -5.10 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a 50 day moving average of $6.87 and a 200-day moving average of $7.06.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter in the prior year, the company earned ($0.43) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% on a year-over-year basis. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total value of $94,800.00. Following the transaction, the chief financial officer now owns 1,426,506 shares in the company, valued at approximately $9,015,517.92. This represents a 1.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at $3,288,380.78. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 70,341 shares of company stock valued at $488,290 in the last quarter. Company insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its position in shares of Recursion Pharmaceuticals by 20.3% in the second quarter. Bank of New York Mellon Corp now owns 1,060,804 shares of the company’s stock worth $7,956,000 after buying an additional 178,994 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Recursion Pharmaceuticals by 39.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 49,863 shares of the company’s stock valued at $374,000 after acquiring an additional 14,060 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in Recursion Pharmaceuticals by 25.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 44,241 shares of the company’s stock worth $332,000 after purchasing an additional 9,058 shares during the last quarter. Rhumbline Advisers boosted its position in Recursion Pharmaceuticals by 24.1% during the second quarter. Rhumbline Advisers now owns 281,348 shares of the company’s stock worth $2,110,000 after purchasing an additional 54,576 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after purchasing an additional 2,598 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.